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Shades of Gray
Peters and colleagues examined differentially regulated 
genes in pigmented, gray, and white hairs from each of five 
donors to profile the aging process in human anagen hair fol-
licles. Expression of melanocyte biology–associated mark-
ers was altered in accord with biological hair follicle age. 
Furthermore, glutamate metabolism with optimal glutamine 
concentrations was crucial for maintaining hair growth and 
pigmentation, whereas suboptimal concentrations promoted 
an aging-like process in culture. Thus, graying hair appears to 
be a valid model for exploring the aging process and identify-
ing targets for therapeutic interventions. See page 1150
Finicky towards Flora
van der Aar and colleagues describe the 
mechanisms employed by resident immune 
cells to prevent harmful T-cell responses 
against skin bacteria. Despite the localiza-
tion of Langerhans cells (LCs) to the outer-
most layer of skin, these dendritic cells are 
poor activators of bacteria-specific T cells, in 
part because of their poor bacterial internal-
ization, degradation, and major histocom-
patibility complex class II antigen loading, 
whereas dermal dendritic cells are poised 
to present antigen for antibacterial immune 
responses following penetration of pathogen 
to the dermis. In addition, LCs induce a high 
percentage of bacteria-specific regulatory T 
cells, supporting the hypothesis that LCs play an important role in maintaining toler-
ance to the resident bacterial skin flora. See page 1240
Dual-Action Blocker
Hypertrophic scarring (HPS) 
results from increased fibro-
genesis that stems from exag-
gerated inflammation in 
combination with mechani-
cal stress following trauma 
or surgery. A lack of effective 
therapy prompted Liu and col-
leagues to examine the effects 
of the bioactive product xiamenmycin on HPS. Interestingly, xiamenmycin inhibited 
scar formation in a mechanical stretch-induced mouse model via reduction of CD4+ 
T lymphocytes and monocyte/macrophage retention as well as blockade of adhesion 
of monocytes and fibroblasts. Furthermore, xiamenmycin attenuated the effects of 
mechanical stress by interrupting several signaling pathways. Because xiamenmycin 
inhibits both inflammation and mechanotransduction, this compound is a promising 
candidate for treating HPS. See page 1351
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Following the Signals
Oncogenic BRAF (BRAFV600E), 
which is found in ~50% of 
melanoma cases, promotes 
the epithelial-to-mesenchymal 
transition—presumably by 
E-cadherin loss, which is also 
common in melanoma. Boyd 
and colleagues found that 
oncogenic BRAF specifically 
suppresses E-cadherin 
transcription via upregulation 
of the Tbx3 transcriptional 
repressor in melanoma cells 
and that expression of Tbx3 
correlated with BRAF mutation 
in human melanoma samples. 
This increased expression of 
Tbx3 in concert with oncogenic 
BRAF function promoted 
melanoma cell invasion. 
Identification of downstream 
players in melanoma will be 
useful for developing new 
strategies to treat this highly 
aggressive cancer. See page 1269
It’s in Their Blood
The changing landscape of 
targeted noncytotoxic therapies 
for melanoma highlights the 
need for simple, noninvasive 
tests to sensitively detect 
the presence of subclinical 
disease and/or early relapse. 
Lo Nigro and colleagues 
found that methylation of 
TFP12—a gene that encodes 
tissue factor pathway inhibitor 
2, suspected to exert tumor 
suppressor functions—is 
a promising biomarker for 
metastatic melanoma. TFP12 
was methylated in both primary 
and metastatic melanomas 
with a significant increase in 
metastatic samples. Importantly, 
detection of TFP12 methylation 
in serum samples from patients 
with resected melanoma was 
correlated with metastatic 
disease. See page 1278
